Health Care [ 4/12 ] | Biotechnology [ 17/74 ]
NASDAQ | Common Stock
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.
Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam.
The company was incorporated in 2013 and is based in Shanghai, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -0.80 Increased by +20.00% | -0.63 Decreased by -26.32% |
| Nov 12, 24 | -0.42 Increased by +40.85% | -0.78 Increased by +46.15% |
| Aug 6, 24 | -0.80 Increased by +36.00% | -0.71 Decreased by -12.68% |
| May 8, 24 | -0.50 Increased by +1.96% | -0.92 Increased by +45.65% |
| Feb 27, 24 | -1.00 Decreased by -53.85% | -0.86 Decreased by -16.28% |
| Nov 7, 23 | -0.71 Increased by +57.74% | -1.04 Increased by +31.73% |
| Aug 7, 23 | -1.25 Increased by +13.19% | -0.79 Decreased by -58.23% |
| May 9, 23 | -0.51 Increased by +43.33% | -0.95 Increased by +46.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 109.07 M Increased by +65.68% | -81.68 M Increased by +14.40% | Decreased by -74.89% Increased by +48.34% |
| Sep 30, 24 | 102.27 M Increased by +47.72% | -41.67 M Increased by +39.74% | Decreased by -40.75% Increased by +59.21% |
| Jun 30, 24 | 100.50 M Increased by +45.95% | -80.28 M Increased by +33.60% | Decreased by -79.87% Increased by +54.50% |
| Mar 31, 24 | 87.15 M Increased by +38.78% | -53.47 M Decreased by -210.93% | Decreased by -61.36% Decreased by -124.05% |
| Dec 31, 23 | 65.83 M Increased by +5.16% | -95.43 M Decreased by -263.61% | Decreased by -144.96% Decreased by -245.77% |
| Sep 30, 23 | 69.23 M Increased by +20.31% | -69.15 M Increased by +64.32% | Decreased by -99.89% Increased by +70.34% |
| Jun 30, 23 | 68.86 M Increased by +42.94% | -120.89 M Increased by +31.76% | Decreased by -175.56% Increased by +52.26% |
| Mar 31, 23 | 62.80 M Increased by +34.40% | -17.20 M Increased by +79.72% | Decreased by -27.39% Increased by +84.91% |